Mycoplasma Testing Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Japan, China, India, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025
Report ID: GMI4112
Mycoplasma Testing Market size is projected to experience significant growth from 2019 to 2025.
Increasing spending on R&D activities by various biopharmaceutical companies coupled with growing governmental initiatives for and funding in research activities will be the major factors leading to growth of mycoplasma testing market growth in the future. For instance, in February 2019, U.S. FDA proposed amendment of biologics regulation for mycoplasma testing to accommodate novel technologies and tests. Aforementioned factors will boost the mycoplasma testing market growth across the forecast timeframe.
Various technological advancements will spur the growth of mycoplasma testing market growth. For instance, American Type Culture Collection (ATCC) announced development and launch of novel PCR-based mycoplasma testing service that enables detection of more than 60 species of mycoplasma in less time. Increasing demand for accurate, fast and affordable testing are the major drivers of mycoplasma testing market growth.
However, stringent government regulations across emerging and developed countries coupled with high entry barrier for new market players due to consolidation will hinder the mycoplasma testing market growth.
The kits & reagent segment is expected to dominate the overall mycoplasma testing market. Repeated purchase of kits and reagents as compared to instruments and growing use of kit-based techniques will be the major growth driving factor across the forecast timeframe. Additionally, stringent government norms to ensure product safety will further boost the demand for kits and reagents segment, thus leading to market growth.
Growing expenditure on R&D activities for development of novel mycoplasma testing procedures will be a major factor for growth of PCR-based tests. Low cost of PCR mycoplasma detection kits coupled with high sensitivity and accuracy are some of the advantages of PCR-based detection kits, thereby fostering market growth. Additionally, convenient, fast and reliable in-situ detection of mycoplasma leads to higher preference for PCR-based mycoplasma detection kits, thereby leading to industry growth in the future.
Application of mycoplasma in cell line testing segment is forecasted to show robust growth in the future. Mycoplasma infection in cell line occurs majorly from laboratory workers due to higher rate of human mycoplasma contamination. Growing use of cell lines for R&D across various research institutes and biopharmaceutical production will positively boost business growth.
Hospitals segment is forecasted to show considerable growth during the analysis period. Growing pervasiveness of multi-drug resistant (MDR) tuberculosis coupled with increasing demand for diagnostic procedures will boost market growth in hospitals. Additionally, development of healthcare infrastructure and increasing investment by various governments to decrease the burden of tuberculosis will offer growth opportunities to drive the segmental growth.
North America mycoplasma testing market is estimated to dominate the overall market during the projection period. High growth is attributed to rising prevalence of chronic diseases and well-established healthcare industry in the region. Moreover, presence of global biotech and pharmaceutical companies, rising healthcare expenditure and higher investment into R&D activities in the region will spur market growth.
Asia Pacific mycoplasma testing market will dominate the overall market during the forecast period due to increasing development and manufacturing of generics in pharmaceutical industry in this region. Various government investments to support pharmaceutical R&D along with the increasing virus screening will propel the Asia-Pacific market growth across the forecast timeframe.
Few of the key companies operating in mycoplasma testing market include Abbott, Agilent Technologies, Charles River Laboratories, Eurofins Scientific, Roche Ltd, Lonza Group, Merck, PromoCell GmbH, Sartorius AG, and Thermo Fisher Scientific. The industry players focus on strategic initiatives such as geographic expansion mergers, new product launch and acquisitions to maintain their market position.
Mycoplasma Testing Market by Product, 2014-2025 (USD Million)
- Kits & reagents
- PCR Assays
- Nucleic Acid Detection Kits
- Elimination Kits
- Standards & Controls
Mycoplasma Testing Market by Technology, 2014-2025 (USD Million)
- Direct Assay
- Indirect Assay
- Enzymatic Methods
- DNA Staining
Mycoplasma Testing Market by Application, 2014-2025 (USD Million)
- Cell Line Testing
- Virus Testing
Mycoplasma Testing Market by End-use, 2014-2025 (USD Million)
- Academic Research Institutes
- Cell Banks
- Pharmaceutical & Biotechnology Companies
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Agilent Technologies
- Charles River Laboratories
- Eurofins Scientific
- Roche Ltd
- Lonza Group
- PromoCell GmbH
- Sartorius AG
- Thermo Fisher Scientific
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Why Global Market Insights, Inc.?
- GMI is unparalleled when to comes to the quality of research and information provided to clients. Our unique methodology is designed to ensure a minimum of 90% accuracy to give our clients excellent value on their investment.
Over 200 experts are available across various time-zones, ready to serve clients for their research needs. Our industry experts help clients to design reports customized to their needs.